Skip to main content Skip to navigation
We care about your privacy. Read about your rights and how we protect your data. Get Details

Coronavirus Update:What patients and families need to know

Program: Immunotherapy for Controlling Inflammation

Image banner for immunotherapy project

Key Personnel

  • Patrick Hanley, Ph.D. 
  • Allistair Abraham, M.D. 
  • David Jacobsohn, M.D. 
  • Maria Martin Manso, Ph.D. 
  • Renuka Miller, Ph.D. 
  • Min Luo, Ph.D. 
  • Catherine Bollard, M.D. 
  • Sawa Ito, M.D. (NIH) 
  • John Barrett, M.D. (NIH) 
  • Jacques Galipeau, M.D. (Emory)

Anti-inflammatory mesenchymal stromal cells (MSCs) have shown great promise in modulating inflammatory syndromes inflammatory bowel disease. These properties make them ideal candidates to develop a product bank that can be readily used by patients as an “off the shelf” therapeutic. We have validated a novel, automated bioreactor system also allows for consistent cell feeding via perfusion, which allows better reproducibility, scalability, and healthier cells. Preclinical experiments show that their anti-inflammatory properties are enhanced using this expansion method. Our goal is to manufacture these anti-inflammatory cells using our rapid expansion system and use them for a variety of clinical indications. Our initial focus is graft versus host disease and inflammatory bowel disease, but ultimately we will explore the use of MSCs for neurological disorders, ARDS, and inflammatory disorders in the neonate such as NEC.: We aim to manufacture bone marrow-derived mesenchymal stromal cells using a rapid expansion system, using the quantum bioreactor, and show reproducible function and phenotype of our clinical-grade products. We are now manufacturing products for clinical use and initiating clinical trials for pediatric and young adult patients with GVHD and inflammatory bowel disease.